TTNT of patients with CLL treated with Ibrutinib. Patients with CLL treated with ibrutinib in later lines (yellow line) compared to those in the first or second lines (purple line).
Figure 1.

TTNT of patients with CLL treated with Ibrutinib. Patients with CLL treated with ibrutinib in later lines (yellow line) compared to those in the first or second lines (purple line).

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal